Seres Therapeutics Inc (MCRB) Implied Volatility Current

Tracking MCRB implied volatility helps you identify when options premiums on Seres Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Seres Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when MCRB IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Seres Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For MCRB, tracking metrics like MCRB IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on MCRB signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants.

In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where MCRB implied volatility sits today versus where it has been. Our scanner ranks Seres Therapeutics Inc implied volatility against its historical range, surfaces extremes in MCRB IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Seres Therapeutics Inc IV is rich or cheap — measure it, then act on it.